Business Description
MoonLake Immunotherapeutics
NAICS : 541720
SIC : 2833
ISIN : KY61559X1045
Share Class Description:
MEX:MLTX: Class ADescription
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 133.93 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | -63.43 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 100 | |||||
| 6-1 Month Momentum % | 9.94 | |||||
| 12-1 Month Momentum % | 9.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 25.51 | |||||
| Quick Ratio | 25.51 | |||||
| Cash Ratio | 24.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.92 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -16.34 | |||||
| ROA % | -15.22 | |||||
| ROIC % | -937.42 | |||||
| ROC (Joel Greenblatt) % | -2645.87 | |||||
| ROCE % | -20.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.98 | |||||
| Price-to-Tangible-Book | 5.98 | |||||
| EV-to-EBIT | -22.46 | |||||
| EV-to-EBITDA | -22.48 | |||||
| EV-to-Forward-Revenue | 30.21 | |||||
| EV-to-FCF | -30.17 | |||||
| Price-to-Net-Current-Asset-Value | 6.05 | |||||
| Price-to-Net-Cash | 6.29 | |||||
| Earnings Yield (Greenblatt) % | -4.45 | |||||
| FCF Yield % | -2.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MoonLake Immunotherapeutics Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -23.478 | ||
| Beta | 0 | ||
| Volatility % | 30.99 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (MXN) | 1.576235 | ||
| 20-Day SMA (MXN) | 1074.2 | ||
| 12-1 Month Momentum % | 9.94 | ||
| 52-Week Range (MXN) | 977.05 - 1074.2 | ||
| Shares Outstanding (Mil) | 63.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MoonLake Immunotherapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MoonLake Immunotherapeutics Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
MoonLake Immunotherapeutics Frequently Asked Questions
What is MoonLake Immunotherapeutics(MEX:MLTX)'s stock price today?
The current price of MEX:MLTX is MXN1074.20. The 52 week high of MEX:MLTX is MXN1074.20 and 52 week low is MXN977.05.
When is next earnings date of MoonLake Immunotherapeutics(MEX:MLTX)?
The next earnings date of MoonLake Immunotherapeutics(MEX:MLTX) is 2025-02-28 Est..
Does MoonLake Immunotherapeutics(MEX:MLTX) pay dividends? If so, how much?
MoonLake Immunotherapeutics(MEX:MLTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers